Handok

Handok Tangible Book Value per Share

The Tangible Book Value per Share of Handok (002390.KS) as of Oct 21, 2026 is 16,863.84 KRW. In the previous year, Tangible Book Value per Share was 14,736.86 KRW — a change of 14.43% (higher).

Tangible Book Value per Share

16,863.84KRW

YoY

14.43%

Last updated:

Tangible Book Value per Share of Handok is 2025 16,863.84 KRW. Tangible Book Value per Share of Handok was 2024 14,736.86 KRW. It decreases by 14.43% higher compared to the previous year.

The Handok Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
15,143.05 KRW
Jan 1, 2019
17,751.91 KRW
Jan 1, 2020
21,020.71 KRW
Jan 1, 2021
22,007.83 KRW
Jan 1, 2022
21,584.19 KRW
Jan 1, 2023
18,585.75 KRW
Jan 1, 2024
14,736.86 KRW
Jan 1, 2025
16,863.84 KRW
The Handok Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
16,863.84KRW+14.43%
14,736.86KRW-20.71%
18,585.75KRW-13.89%
21,584.19KRW-1.92%
22,007.83KRW+4.70%
21,020.71KRW+18.41%
17,751.91KRW+17.23%
15,143.05KRW+12.39%
13,474.20KRW+1.51%
13,274.23KRW-20.35%
16,666.05KRW-4.21%
17,398.13KRW-24.22%
22,960.08KRW+3.46%
22,192.42KRW+3.15%
21,513.67KRW+2.69%
20,950.00KRW+26.72%
16,532.25KRW+9.85%
15,050.33KRW-0.16%
15,074.83KRW+4.17%
14,471.67KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Handok stock

Tangible Book Value per Share of Handok is 16,863.84 KRW in 2025.

Tangible Book Value per Share of Handok changed from 14,736.86 KRW to 16,863.84 KRW, representing a 14.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Handok since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Handok

All Key Metrics — Handok